Vertex- Scottish govt. sign cystic fibrosis treatment access contract
Category: #health  By Mateen Dalal  Date: 2019-09-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Vertex- Scottish govt. sign cystic fibrosis treatment access contract

As part of the 5-year agreement, Vertex will also be collecting real world data on these medicines.

Vertex Pharmaceuticals Incorporated has reportedly announced that Scotland based patients suffering from cystic fibrosis will now be eligible to have access to ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) in combination with ivacaftor subsequently after signing an agreement for access.

Ludovic Fenaux, Senior VP, Vertex International, reportedly stated that the company would like to appreciate the Scottish authorities for their partnership and the flexible and collaborative way which helped both of the entities have worked together to figure out an access solution. It means that about 400 eligible patients suffering from cystic fibrosis in Scotland will now be able to have access to SYMKEVI or ORKAMBI, he further added.

Apparently, as part of the 5-year agreement, Vertex will also be collecting real world data on these medicines. This data will further support any future submissions to the Scottish Medicines Consortium (SMC).

Reportedly, Vertex cystic fibrosis medicines have been reimbursed in 17 countries around the world. These 17 countries include Australia, Austria, Denmark, Germany, Italy, the Republic of Ireland, the Netherlands, the U.S. and Sweden.

According to reliable sources, around 900 people in Scotland are suffering from CF. In the United Kingdom, 32 years is the median age of death of people suffering from CF. NHS Scotland has estimated that one in 24 Scots have a CFTR mutation. If this mutation is carried by both parents then it may lead to a baby being born with CF.

For the record, Vertex is a multinational biotechnology firm which invests in innovative initiatives to develop medicines for patients suffering from serious disorders. The company owns three approved medicines which can treat the primary cause of cystic fibrosis (CF).  Cystic fibrosis is a rare and life-threatening genetic disorder. There are several ongoing clinical and research programs going on to develop efficient treatment of CF.

Source Credit:

https://www.businesswire.com/news/home/20190912005349/en/Vertex-Announces-New-Access-Agreement-Scottish-Government

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Dermtech signs a commercial & medicare advantage coverage agreement
Dermtech signs a commercial & medicare advantage coverage agreement
By Mateen Dalal

DermTech Inc., a San Diego based biotechnology company that is involved in precision dermatology, has recently announced signing a contract with a regional health plan to develop its gene expression based PLA (Pigmented Lesion Assay) for prior detect...

CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
By Mateen Dalal

The merger will bring two therapeutic immune-oncology platforms together Focus shall be placed over Phase 1 and Phase 2 trials of CAR-CIK and CMN-001 respectively U.S.-based bioscience firm CoImmune, Inc., announces partnership with Formula Phar...

Adverum reviews recent business progress and unveils its 2020 outlook
Adverum reviews recent business progress and unveils its 2020 outlook
By Mateen Dalal

Adverum Biotechnologies, a California based biotech company, has reportedly announced that it has examined its recent business & development progress. The company has also unveiled its outlook for 2020. Leone Patterson, president and chief execu...